Skip to content

Multicenter Registry of Coronary Flow-Derived Indexes for Coronary Microvascular Disease (Multicenter FLOW-CMD Registry)

Prospective Registry of Coronary Flow-Derived Indexes in Patients With Coronary Artery Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05369182
Enrollment
1003
Registered
2022-05-11
Start date
2022-04-22
Completion date
2027-12-31
Last updated
2026-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Coronary Microvascular Disease, Ischemic Heart Disease

Keywords

Coronary Microvascular Disease, Coronary Artery Disease, Ischemic Heart Disease, Coronary Flow Reserve, Index of Microcirculatory Resistance, Fractional Flow Reserve, Intravascular Ultrasound, Optical Coherence Tomography

Brief summary

Multicenter FLOW-CMD registry is a prospective, multi-center, registry study. The aim of the study is to evaluate prognostic implications of coronary microvascular disease (CMD) in patients with ischemic heart disease (IHD) undergoing revascularization decision using FFR or other non-hyperemic pressure ratios.

Detailed description

The diagnostic and therapeutic strategies in patients with coronary artery disease (CAD) have focused on identifying and alleviating both extent and severity of myocardial ischemia, as it is the most important prognostic fator. Thus, fractional flow reserve (FFR) has been a standard method for identifying ischemia-related epicardial coronary stenosis, accruing an abundance of clinical evidence on the benefit of FFR-guided treatment decisions. However, a high FFR value (\>0.80) does not necessarily imply freedom from future events. Indeed, clinical events still occur in patients who are deferred based on high FFR. The microvasculature is one of the main components of coronary circulatory system, and the presence of microvascular disease may contribute to clinical events in patients without epicardial coronary stenosis. In the cardiac catheterization laboratory, microvascular disease can be assessed using a pressure/temperature-sensor coronary wire or a Doppler wire. Previous studies have demonstrated the incremental prognostic implications of coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) in patients with high FFR, and the recent European guidelines supported the importance of invasive physiologic assessment using CFR and IMR in patients with stable coronary artery disease. Furthermore, recent Expert Consensus Documents and the European Society of Cardiology guideline of Chronic Coronary Syndrome have underlined the importance of evaluating coronary microvascular disease (CMD) in patients with ischemic heart disease (IHD) and proposed an universal definition of CMD based on: 1) functionally non-obstructive CAD defined by a fractional flow reserve (FFR)\>0.80 and 2) impaired coronary microvascular function determined by abnormal CFR and/or microvascular resistance. Another important issue in contemporary practice is how to improve patient prognosis after percutaneous coronary intervention (PCI). Although PCI can induce secondary CMD originated from multiple mechanism associated with the procedure (e.g. distal embolization or endothelial dysfunction), and although secondary CMD also affects coronary circulatory function, there has been no previous evidence evaluating the incidence and prognosis of secondary CMD after successful PCI for epicardial coronary stenosis. Furthermore, both previous and recent trials demonstrated that intravascular imaging-guided PCI optimization has significantly better clinical outcomes than angiography-only guided PCI. However, these trials could not explain the exact mechanism underlying the potential benefit of intravascular imaging-guided PCI optimization for better clinical outcome, aside from a larger final stent area following intravascular imaging-guided PCI. Although the fundamental purpose of PCI is to resolve inducible myocardial ischemia originated from epicardial coronary stenosis, several studies have demonstrated that a substantial proportion of patients who underwent angiographically successful PCI had suboptimal post-PCI FFR or non-hyperemic pressure ratios, which are independently associated with worse clinical outcomes. Previous studies demonstrated that intravascular imaging devices could identify correctable cause of suboptimal post-PCI FFR. In this regard, it can be expected that intravascular imaging-guided PCI optimization would result in better post-PCI physiologic results such as higher post-PCI FFR and CFR, compared with angiography-only guided PCI. However, these issues have not been fully clarified. Regarding the prognostic impact of CMD, only limited data has been available on the prognostic implications of CMD defined by the universal definition among patients with IHD, especially in patients with insignificant epicardial coronary disease defined by FFR\>0.80. In addition, only one prospective study evaluated optical coherence tomography (OCT)-guided PCI for post-PCI FFR in patients with non-ST segment elevation myocardial infarction. None of prospective study evaluated potential physiologic benefit of intravascular imaging-guided PCI optimization using intravascular ultrasound (IVUS) or OCT in unselected patient population. Therefore, the primary objectives of the current multicenter prospective registry are to evaluate prognostic implications of CMD in patients with suspected IHD undergoing revascularization decision using FFR or other non-hyperemic pressure ratios and to evaluate the efficacy of intravascular imaging-guided optimization to enhance post-revascularization coronary circulatory function, compared with angiography-only guided revascularization in revascularized population.

Interventions

DIAGNOSTIC_TESTInvasive physiologic assessment

All coronary physiologic parameters are measured following diagnostic angiography. Resting pd/pa, FFR, CFR and IMR will be calculated using coronary physiologic parameters. In patients treated by PCI, post-PCI physiologic assessment including CFR, IMR, and FFR will be performed.

DIAGNOSTIC_TESTIntravascular imaging

By the operator's discretion, stent-optimization will be performed under intravascular imaging devices (IVUS \[Boston Scientific, Natick, Massachusetts, USA\] or OCT \[Abbott Vascular\], St. Paul, MN, USA\]).

Sponsors

Samsung Medical Center
Lead SponsorOTHER
Chonnam National University Hospital
CollaboratorOTHER
Chosun University Hospital
CollaboratorOTHER
Seoul National University Bundang Hospital
CollaboratorOTHER
Seoul St. Mary's Hospital
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Subject must be ≥18 years 2. Patients suspected with IHD 3. Patients undergoing physiologic assessment (CFR, IMR, and FFR) for evaluation of severity of CAD 4. Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic or imaging evaluation and he/she or his/her legally authorized representative provides written informed consent to any study related procedure.

Exclusion criteria

1. Cardiogenic shock (systolic blood pressure \<90mmHg or requiring inotropics to maintain blood pressure \>90mmHg) or cardiac arrest 2. Non-cardiac co-morbid conditions are present with life expectancy \<2 year (per site investigator's medical judgment). 3. Inability to undergo physiologic assessment (CFR, IMR, and FFR) 4. Pregnant or lactating women

Design outcomes

Primary

MeasureTime frameDescription
Patient-oriented composite outcomes (POCO)1 year after last patient enrollmenta composite of all-cause death, MI, any repeat revascularization, or admission for heart failure

Secondary

MeasureTime frameDescription
All-cause death1 year after last patient enrollmentAll-cause death
Cardiac death1 year after last patient enrollmentCardiac death
Target-vessel MI1 year after last patient enrollmentTarget-vessel MI
Non-target vessel MI1 year after last patient enrollmentNon-target vessel MI
Any MI1 year after last patient enrollmentAny MI
Target vessel revascularization (clinically-driven or all)1 year after last patient enrollmentTarget vessel revascularization (clinically-driven or all)
Non-target vessel revascularization (clinically-driven or all)1 year after last patient enrollmentNon-target vessel revascularization (clinically-driven or all)
Any repeat revascularization (clinically-driven or all)1 year after last patient enrollmentAny repeat revascularization (clinically-driven or all)
Admission for congestive heart failure1 year after last patient enrollmentAdmission for congestive heart failure
Stroke (ischemic and hemorrhagic)1 year after last patient enrollmentStroke (ischemic and hemorrhagic)
Seattle Angina QuestionnaireBaseline, 1 year, and 2 year after patient enrollmentPhysical limitation, Angina stability, Angina frequency, Treatment satisfaction, Quality of life
Proportion of functionally optimized post-PCI resultsPost-procedureProportion of functionally optimized post-PCI results (Post-PCI FFR\>0.80 and CFR\>2.0) according to the use of intravascular imaging
Incidence of secondary CMD after PCIPost-procedureIncidence of secondary CMD (CFR\<2.0 and IMR≥25) after PCI among revascularized population

Countries

South Korea

Contacts

PRINCIPAL_INVESTIGATORJoo Myung Lee, MD, MPH, PhD

Samsung Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 23, 2026